Fibromyalgia syndrome

Journal of Rheumatology

Volumn 34, Issue 6, 2007, Pages 1415-1425

  Mease, Philip J ^a,b,u   Arnold, Lesley M ^c   Bennett, Robert ^d   Boonen, Annelies ^e   Buskila, Dan ^f   Carville, Serena ^g   Chappell, Amy ^h   Choy, Ernest ^g   Clauw, Daniel ⁱ   Dadabhoy, Dina ⁱ   Gendreau, Michael ^j   Goldenberg, Don ^k,l   Littlejohn, Geoffrey ^m,n   Martin, Susan ^o   Perera, Philip ^p   Russell, I Jon ^q   Simon, Lee ^r   Spaeth, Michael ^s   Williams, David ⁱ   Crofford, Leslie ^t  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h ELI LILLY AND COMPANY   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j Cypress Bioscience Inc   (United States)

^k NEWTON WELLESLEY HOSPITAL   (United States)

^l TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m MONASH MEDICAL CENTRE   (Australia)

ⁿ MONASH UNIVERSITY   (Australia)

^o PFIZER INC   (United States)

^p JAZZ PHARMACEUTICALS   (United States)

^q University of Texas Health Science Center   (United States)

^r BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^s LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^t UNIVERSITY OF KENTUCKY   (United States)

^u Seattle Rhumatology Associates   (United States)

more..

Author keywords

Fibromyalgia; Omeract; Outcome measures; Pain

Indexed keywords

ANALGESIC AGENT; LIOTHYRONINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; AEROBIC EXERCISE; BALNEOTHERAPY; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COGNITIVE THERAPY; CONFERENCE PAPER; DELPHI STUDY; DISABILITY; FATIGUE; FIBROMYALGIA; HOMEOPATHY; HUMAN; INFORMATION SYSTEM; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MOOD; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PAIN; PAIN ASSESSMENT; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SLEEP; STANDARDIZATION; VALIDATION PROCESS;

DISABILITY EVALUATION; FIBROMYALGIA; FOCUS GROUPS; HEALTH STATUS INDICATORS; HUMANS; INTERNATIONAL COOPERATION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PARTICIPATION; QUALITY ASSURANCE, HEALTH CARE; REPRODUCIBILITY OF RESULTS;

EID: 34250176930     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
2. Croft P, Rigby AS, Boswell R, et al. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993;20:710-3.
3. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
4. Bennett RM. Emerging concepts in the neurobiology of chronic-pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999;74:385-98.
5. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701.
6. Crofford LJ, Clauw DJ. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum 2002;46:1136-8.
7. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005;32 Suppl 75:6-21.
8. Pillemer SR, Bradley LA, Crofford LJ, et al. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997;40:1928-39.
9. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-13.
10. Barkhuizen A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002;28:261-90.
11. Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002;28:181-99.
12. Rao SG, Bennett RM. Pharmacological therapies in fibromyalgia. Best Pract Res Clin Rheumatol 2003;17:611-27.
13. Sprott H. What can rehabilitation interventions achieve in patients with primary fibromyalgia? Curr Opin Rheumatol 2003;15:145-50.
14. Williams DA. Psychological and behavioural therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:649-65.
15. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005;32:2270-7.
16. Bennett RM. Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol 1998;57 Suppl 2:72-6.
17. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45.
18. Gendreau M, Mease P, Rao S, et al. Milnacipran: A potential new treatment of fibromyalgia [abstract]. Arthritis Rheum 2003;48 Suppl:S616.
19. Rowe G, Wright G, Bolger F, Delphi. A reevaluation of research and theory. Technological Forecasting and Social Change 1991;39:235-51.
20. Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7.
21. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84.
22. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15.
23. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31.
24. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73.
25. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495-505.
26. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19 Suppl 1:S27-35.
27. Adams N, Sim J. Rehabilitation approaches in fibromyalgia. Disabil Rehabil 2005;27:711-23.
28. Baker K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep 2005;9:301-6.
29. Crofford LJ. Meta-analysis of antidepressants in fibromyalgia. Curr Rheumatol Rep 2001;3:115.
30. Crofford LJ, Appleton BE. The treatment of fibromyalgia: a review of clinical trials. Curr Rheumatol Rep 2000;2:101-3.
31. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95.
32. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain 2002;18:324-36.
33. Russell I, Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7.
34. Alanoglu E, Ulas UH, Ozdag F, et al. Auditory event-related brain potentials in fibromyalgia syndrome. Rheumatol Int 2005;25:345-9.
35. Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005;52:1577-84.
36. Klein R, Berg PA. High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res 1995;1:21-6.
37. Buskila D, Neumann L. Genetics of fibromyalgia. Curr Pain Headache Rep 2005;9:313-5.
38. Crofford LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and Cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 2004;18:314-25.
39. Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 1998;315:377-84.
40. Evengard B, Nilsson CG, Lindh G, et al. Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998;78:153-5.
41. Gur A, Karakoc M, Nas K, et al. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002;29:358-61.
42. Maekawa K, Twe C, Lotaif A, et al. Function of beta-adrenergic receptors on mononuclear cells in female patients with fibromyalgia. J Rheumatol 2003;30:364-8.
43. Petzke F, Clauw DJ, Ambrose K, et al. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003;105:403-13.
44. Julien N, Goffaux P, Arsenault P, et al. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005;114:295-302.
45. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 2000;88:69-78.
46. Buskila D, Press J. Neuroendocrine mechanisms in fibromyalgia-chronic fatigue. Best Pract Res Clin Rheumatol 2001;15:747-58.
47. Glass JM, Lyden AK, Petzke F, et al. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 2004;57:391-8.
48. Landis CA, Lentz MJ, Tsuji J, et al. Pain, psychological variables, sleep quality, and natural killer cell activity in midlife women with and without fibromyalgia. Brain Behav Immun 2004;18:304-13.
49. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
50. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
51. Tugwell P, Bombardier C. A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982;9:758-62.
52. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
53. Cieza A, Stucki G, Weigl M, et al. ICF Core Sets for chronic widespread pain. J Rehabil Med 2004;44 Suppl:63-8.
54. Cella D, Chang CH. A discussion of item response theory and its applications in health status assessment. Med Care 2000;38:1166-72.
55. Cook KF, O'Malley KJ, Roddey TS. Dynamic assessment of health outcomes: time to let the CAT out of the bag? Health Serv Res 2005;40:1694-711.
56. Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol 2005;23:S53-7.